Clinical Evidence: Wegovy vs Mounjaro Weight Loss Data
Which Is Better Wegovy or Mounjaro: Understanding the Clinical Evidence
When evaluating which is better Wegovy or Mounjaro for UK patients, the clinical evidence reveals important distinctions between these prescription-only medicines. Wegovy (semaglutide) demonstrated approximately 15% average weight loss at 68 weeks in the landmark STEP 1 trial, whilst maintaining this reduction over 2 years in STEP 5 studies. Mounjaro (tirzepatide) showed varying results across different doses in SURMOUNT trials, though direct head-to-head comparisons remain limited due to different trial designs and patient populations.
The key difference lies in their mechanisms of action rather than superior efficacy claims. Wegovy specifically targets GLP-1 receptors to reduce appetite and promote satiety, whilst Mounjaro activates both GIP and GLP-1 pathways as a dual agonist. Both treatments require prescription alongside a reduced-calorie diet and increased physical activity, making the choice highly individual based on your health profile and prescriber guidance.
Wegovy vs Mounjaro Pricing: UK Treatment Costs Compared
Understanding the financial commitment helps determine which is better Wegovy or Mounjaro for your budget and treatment duration. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99.
Mounjaro follows a different pricing structure due to its distinct formulation and dosing schedule. Both treatments represent significant investments in long-term weight management, requiring ongoing monthly costs for sustained results. The choice between treatments should prioritise clinical suitability and prescriber recommendations rather than cost alone, as both require long-term commitment for optimal outcomes.
STEP Trial Results: Wegovy Weight Loss Evidence in Clinical Practice
The STEP clinical trial programme provides robust evidence for patients questioning which is better Wegovy or Mounjaro based on documented outcomes. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated enhanced results of approximately 16% when combined with intensive behavioural therapy.
Critically, STEP 5 showed sustained weight loss of approximately 15.2% at 2 years, whilst the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events. These results represent clinical trial conditions and individual outcomes may vary significantly based on adherence, lifestyle factors, and underlying health conditions.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Understanding how Wegovy functions helps clarify which is better Wegovy or Mounjaro for your physiological needs. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone released when you eat. This mechanism reduces appetite by acting on brain centres that control hunger, whilst simultaneously promoting feelings of fullness after smaller meals. The treatment may also reduce food cravings and slow gastric emptying, helping you feel satisfied longer between meals. As a once-weekly injection using the FlexTouch pen system, Wegovy requires gradual dose escalation over 16 weeks to reach the 2.4mg maintenance dose. This systematic approach minimises side effects whilst optimising therapeutic benefits for sustained weight management.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing Wegovy through our GPhC #9012878 registered pharmacy involves a streamlined process designed for UK patients comparing which is better Wegovy or Mounjaro. The journey begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review each application within 3 working days (or 24 hours with express review), ensuring clinical suitability and safety before approval. Once prescribed, we dispatch Wegovy via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. This process ensures you receive genuine Novo Nordisk Wegovy whilst meeting all MHRA regulatory requirements for prescription-only medicine supply. Our clinical team remains available for ongoing support throughout your treatment journey.
Storage and Practical Considerations: Wegovy vs Mounjaro Convenience
Practical factors often influence decisions about which is better Wegovy or Mounjaro for lifestyle compatibility. Wegovy requires refrigeration at 2-8°C before first use but offers superior travel flexibility with 6 weeks room temperature storage below 30°C once removed from the fridge. In comparison, Mounjaro provides only 21 days room temperature storage, making Wegovy more convenient for extended travel or irregular schedules. The FlexTouch pen system delivers precise doses through a simple injection process, with clear dose escalation from 0.25mg through to 2.4mg maintenance over 16 weeks. Each pen contains four doses for once-weekly administration, and the dose progression cannot be accelerated to minimise gastrointestinal side effects. Proper injection technique and storage compliance directly impact treatment effectiveness and safety outcomes.
UK-Specific Weight Loss Results: Real-World Wegovy vs Mounjaro Outcomes
UK patients often seek local evidence when determining which is better Wegovy or Mounjaro for their circumstances. NHS England's specialist weight management services report varied individual responses to both treatments, with some patients achieving significant weight reduction whilst others experience modest changes. The key factors influencing UK outcomes include adherence to prescribed lifestyle modifications, concurrent medical conditions, and individual metabolic responses to GLP-1 or dual GIP/GLP-1 activation.
NICE guidance TA875 recommends Wegovy specifically within specialist weight management programmes, recognising its evidence base and clinical utility. Both treatments require ongoing commitment to dietary changes and increased physical activity, making success dependent on comprehensive lifestyle modification rather than medication alone. UK prescribers typically consider individual patient factors, treatment history, and potential contraindications when recommending between these options.
Making Your Choice: Expert Guidance for Wegovy vs Mounjaro Selection
Rather than declaring which is better Wegovy or Mounjaro universally, the optimal choice depends on your individual health profile, treatment goals, and clinical factors. Both treatments are available through EverydayMeds, and our qualified prescribers can help determine which option aligns best with your circumstances. This decision involves evaluating your medical history, current medications, lifestyle factors, and personal preferences regarding injection frequency and storage requirements. New customers can begin their assessment today using code FIRST40 at checkout, whilst returning customers apply DOSE25 for established pricing. Our commitment to safe, effective weight management ensures you receive appropriate clinical support regardless of which treatment proves most suitable. Contact our clinical team through the comprehensive online assessment to start your evidence-based weight management journey with professional guidance every step of the way.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
